Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091063 | 0.81 | HCRTR1 (0.38) | NPSR1HCRTR1HCRTR2ATMKMT2A | |
| SCHEMBL25091051 | 0.79 | HCRTR1 (0.33) | NPSR1HCRTR1HCRTR2ATM | |
| SCHEMBL25091056 | 0.77 | NPC1 (0.36) | NPSR1HCRTR1HCRTR2PKMKMT2A | |
| SCHEMBL31298626 | 0.76 | HCRTR1 (0.40) | NPSR1HCRTR1HCRTR2 | |
| SCHEMBL18538040 | 0.75 | HPGD (0.40) | NPSR1HCRTR1HCRTR2MAPK8KMT2A | |
| SCHEMBL18538057 | 0.71 | ADORA2A (0.39) | MAPK8 | |
| SCHEMBL25091062 | 0.70 | HCRTR1 (0.43) | NPSR1HCRTR1HCRTR2 | |
| SCHEMBL18538053 | 0.70 | MAPK8 (0.36) | MAPK8 | |
| SCHEMBL29324752 | 0.69 | GSK3B (0.39) | HCRTR1HCRTR2ATM | |
| SCHEMBL23664926 | 0.68 | HAVCR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | NPSR1 4462/4885HCRTR1 4593/4885HCRTR2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.